Neurovive Pharmaceutical AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.02.20	NeuroVive Pharmaceutical AB Year End Report January - December 2019 (PR Newswire)
19.02.20	NeuroVive Pharmaceutical AB Year End Report January - December 2019 (PR Newswire)
19.02.20	NeuroVive Pharmaceutical AB Year End Report January - December 2019 (PR Newswire)
23.12.19	NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study (PR Newswire)
20.12.19	NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study (PR Newswire)
20.12.19	NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study (PR Newswire)
20.11.19	NeuroVive Pharmaceutical AB Interim Report January - September 2019 (PR Newswire)
20.11.19	NeuroVive Pharmaceutical AB Interim Report January - September 2019 (PR Newswire)
20.11.19	NeuroVive Pharmaceutical AB Interim Report January - September 2019 (PR Newswire)
21.08.19	NeuroVive Pharmaceutical AB Interim Report January - June 2019 (PR Newswire)
21.08.19	NeuroVive Pharmaceutical AB Interim Report January - June 2019 (PR Newswire)
21.08.19	NeuroVive Pharmaceutical AB Interim Report January - June 2019 (PR Newswire)
20.08.19	Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019 (PR Newswire)
28.07.19	NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation (PR Newswire)
27.07.19	NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation (PR Newswire)
27.07.19	NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation (PR Newswire)
04.07.19	NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study (PR Newswire)
04.07.19	NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study (PR Newswire)
04.07.19	NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study (PR Newswire)
21.05.19	NeuroVive Pharmaceutical AB Interim Report January - March 2019 (PR Newswire)
10.05.19	NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA (PR Newswire)
10.05.19	NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA (PR Newswire)
10.05.19	NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA (PR Newswire)
25.03.19	NeuroVive Pharmaceutical AB Publishes 2018 Annual Report (PR Newswire)
25.03.19	NeuroVive Pharmaceutical AB Publishes 2018 Annual Report (PR Newswire)
25.03.19	NeuroVive Pharmaceutical AB Publishes 2018 Annual Report (PR Newswire)
19.03.19	NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study (PR Newswire)
19.03.19	NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study (PR Newswire)
19.03.19	NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study (PR Newswire)
21.02.19	NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds (PR Newswire)
15.11.18	NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders (PR Newswire)
15.11.18	NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders (PR Newswire)
15.11.18	NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders (PR Newswire)
31.10.18	NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1 (PR Newswire)
10.10.18	NeuroVive Receives KL1333 Clinical Trial Regulatory Approval (PR Newswire)
10.10.18	NeuroVive Receives KL1333 Clinical Trial Regulatory Approval (PR Newswire)
10.10.18	NeuroVive Receives KL1333 Clinical Trial Regulatory Approval (PR Newswire)
05.10.18	Edison Investment Research Limited: Edison issues outlook on NeuroVive Pharmaceutical (NVP) (EQS Group)
04.10.18	NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI (PR Newswire)
04.10.18	NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI (PR Newswire)
04.10.18	NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI (PR Newswire)
06.09.18	NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan (PR Newswire)
06.09.18	NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan (PR Newswire)
06.09.18	NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan (PR Newswire)
28.08.18	NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia (PR Newswire)
28.08.18	NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia (PR Newswire)
28.08.18	NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia (PR Newswire)
21.08.18	NeuroVive Pharmaceutical AB Interim Report January - June 2018 (PR Newswire)
21.08.18	NeuroVive Pharmaceutical AB Interim Report January - June 2018 (PR Newswire)
21.08.18	NeuroVive Pharmaceutical AB Interim Report January - June 2018 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	529.50	1.34 %	K V
CieFinRichemont	162.25	1.28 %	K V
Roche Hldg G	309.20	1.01 %	K V
Nestle	91.68	0.50 %	K V
Lonza Grp	568.40	0.25 %	K V
Part Grp Hldg	1’322.50	-1.34 %	K V
Geberit	565.60	-1.39 %	K V
ABB	49.99	-1.63 %	K V
Sika	225.60	-2.42 %	K V
Givaudan	3’913.00	-2.98 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Neurovive Pharmaceutical AB

Aktien Top/Flop

Meistgelesene Nachrichten